Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CRVS
CUSIPN/A
Phone650-900-4520
Debt
Debt-to-Equity RatioN/A
Current Ratio13.69
Quick Ratio13.69
Price-To-Earnings
Trailing P/E Ratio-4.10
Forward P/E Ratio-3.97
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.03 per share
Price / Book2.77
Profitability
EPS (Most Recent Fiscal Year)($2.72)
Net Income$-55,660,000.00
Net MarginsN/A
Return on Equity-51.29%
Return on Assets-46.52%
Miscellaneous
Employees55
Outstanding Shares29,190,000
Corvus Pharmaceuticals (NASDAQ:CRVS) Frequently Asked Questions
What is Corvus Pharmaceuticals' stock symbol?
Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS."
How were Corvus Pharmaceuticals' earnings last quarter?
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) announced its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.74) by $0.11. View Corvus Pharmaceuticals' Earnings History.
What price target have analysts set for CRVS?
4 analysts have issued 1 year price targets for Corvus Pharmaceuticals' stock. Their predictions range from $14.00 to $26.00. On average, they anticipate Corvus Pharmaceuticals' share price to reach $19.00 in the next year. View Analyst Ratings for Corvus Pharmaceuticals.
Are investors shorting Corvus Pharmaceuticals?
Corvus Pharmaceuticals saw a decrease in short interest in the month of May. As of May 31st, there was short interest totalling 873,043 shares, a decrease of 26.5% from the May 15th total of 1,187,813 shares. Based on an average daily trading volume, of 105,039 shares, the short-interest ratio is presently 8.3 days. Currently, 4.4% of the company's shares are sold short. View Corvus Pharmaceuticals' Current Options Chain.
Who are some of Corvus Pharmaceuticals' key competitors?
Some companies that are related to Corvus Pharmaceuticals include Radius Health (RDUS), Pacira Pharmaceuticals (PCRX), Lexicon Pharmaceuticals (LXRX), Impax Laboratories (IPXL), IMMURON Ltd/S (IMRN), Theravance Biopharma (TBPH), Amneal Pharmaceuticals (AMRX), Apellis Pharmaceuticals (APLS), Zai Lab (ZLAB), Athenex (ATNX), Alder Biopharmaceuticals (ALDR), Arrowhead Pharmaceuticals (ARWR), Revance Therapeutics (RVNC), Eagle Pharmaceuticals (EGRX) and Retrophin (RTRX).
Who are Corvus Pharmaceuticals' key executives?
Corvus Pharmaceuticals' management team includes the folowing people:
- Dr. Richard A. Miller M.D., Co-Founder, Chairman, Chief Exec. Officer and Pres (Age 67)
- Dr. Peter A. Thompson, Co-Founder and Director (Age 58)
- Mr. Leiv Lea, CFO & Chief Bus. Officer (Age 64)
- Dr. Joseph J. Buggy Ph.D., Co-Founder and Strategic Advisor (Age 51)
- Mr. Daniel W. Hunt, Sr. VP & Chief Bus. Officer
When did Corvus Pharmaceuticals IPO?
(CRVS) raised $75 million in an IPO on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.
Has Corvus Pharmaceuticals been receiving favorable news coverage?
News coverage about CRVS stock has been trending somewhat negative this week, Accern Sentiment reports. The research group identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Corvus Pharmaceuticals earned a news impact score of -0.04 on Accern's scale. They also gave media headlines about the company an impact score of 48.87 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Corvus Pharmaceuticals' major shareholders?
Corvus Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Adams Street Partners LLC (11.22%), BVF Inc. IL (9.28%), BlackRock Inc. (3.50%), Millennium Management LLC (2.07%), Rock Springs Capital Management LP (1.97%) and Sphera Funds Management LTD. (1.53%). Company insiders that own Corvus Pharmaceuticals stock include Adams Street Partners Llc, Holdings A/S Novo, Orbimed Advisors Llc and Richard A Md Miller. View Institutional Ownership Trends for Corvus Pharmaceuticals.
Which major investors are selling Corvus Pharmaceuticals stock?
Which major investors are buying Corvus Pharmaceuticals stock?
CRVS stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Adams Street Partners LLC, Millennium Management LLC, Rock Springs Capital Management LP, Sphera Funds Management LTD., Dimensional Fund Advisors LP and BlackRock Inc.. Company insiders that have bought Corvus Pharmaceuticals stock in the last two years include Adams Street Partners Llc, Holdings A/S Novo, Orbimed Advisors Llc and Richard A Md Miller. View Insider Buying and Selling for Corvus Pharmaceuticals.
How do I buy shares of Corvus Pharmaceuticals?
Shares of CRVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Corvus Pharmaceuticals' stock price today?
One share of CRVS stock can currently be purchased for approximately $11.16.
How big of a company is Corvus Pharmaceuticals?
Corvus Pharmaceuticals has a market capitalization of $364.91 million. The company earns $-55,660,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Corvus Pharmaceuticals employs 55 workers across the globe.
How can I contact Corvus Pharmaceuticals?
Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The company can be reached via phone at 650-900-4520 or via email at [email protected]
MarketBeat Community Rating for Corvus Pharmaceuticals (CRVS)
MarketBeat's community ratings are surveys of what our community members think about Corvus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
